Santhera Pharmaceuticals AG’s decision to drop steroid-using patients from its study of Duchenne muscular dystrophy candidate Raxone (idebenone) appears to have cost the drugmaker from gaining accelerated approval for patients not using steroids.
Although the Swiss drugmaker previously began its Phase III trial with both steroid non-using and using subgroups, the study was...






